Transplant center directory

The Hematologic Malignancies and Stem Cell Transplant Program at Cancer Treatment Centers of America® (CTCA), Chicago offers patients expertise in diagnosing and treating hematologic diseases using sophisticated technologies and therapies delivered through a personalized approach. The FACT accredited program provides standard-of-care and, when appropriate, advanced medical therapies for hematologic (blood) disorders, including leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma and myelodysplastic syndromes, in both an inpatient and outpatient environment. Once in treatment, patients and their families are cared for by a multidisciplinary team of experts and specialists led by a board-certified hematologic oncologist.

This center has been performing allogeneic transplants since 1998 and has been an NMDP/Be The Match transplant center since September 2011.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 34 patients.

The actual 1-year survival of these patients is 73.5%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 51.8% and 82.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.